Healthy Volunteers
Conditions
Keywords
Safety, Tolerability, Pharmacokinetics, Dose escalation, Randomized, Healthy volunteers, Topical, OLT1177, Olatec, Pain, Inflammation
Brief summary
The purpose of this study is to determine if OLT1177 Gel is safe and can be tolerated when given as a single dose and multidose to a defined area of one knee of healthy subjects.
Detailed description
OLT1177 Gel is being developed for the topical treatment of pain and inflammation emanating from musculoskeletal and certain skin inflammatory conditions. This is a Phase 1 study evaluating the safety and tolerability of OLT1177 Gel in healthy subjects when given as single-dose or multi-dose applications. The study will be conducted in two parts, Part A and Part B. In Part A, approximately 18 healthy subjects in 3 dose escalating cohorts will be randomized to receive a single dose of the investigational drug (5 subjects OLT1177 Gel and 1 subject placebo gel). Upon completion of Part A, a new subject population of approximately 18 subjects in 3 dose escalating cohorts will be randomized in Part B of the study. Subjects will receive a total of 8 doses over 3 consecutive days given 6 hours apart while awake during the day and will be followed for up to 30 days for safety assessment.
Interventions
DRUGOLT1177 Gel
OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee
DRUGPlacebo gel
Sponsors
Olatec Therapeutics LLC
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy men and women 18 to 60 years of age * Women of childbearing potential must have a negative urine pregnancy test within 3 days of study enrollment and must agree to use a highly effective form of contraception * Subjects must be in good health as determined by the Investigator based on medical history, ECG, physical examination and safety laboratory test * Ability to provide written informed consent prior to initiation of any study-related procedures, and ability, in the opinion of the Investigator, to comply with all the requirements of the study
Exclusion criteria
* Subjects with a known hypersensitivity to the investigational drug * Subjects who are pregnant or lactating * Participation in any investigational drug or device study and receipt of any investigational drug or device within the immediate 30 days prior to the start of this study * Concurrent or recent use of analgesics, steroids, allergy medications, H2 blockers within 48 hours of the start of the study * Subjects with a prior knee injury or surgery within the last 5 years * Subjects with an active infection or with a fever ≥ 38°C within 3 days of the start of the study * Subjects with a history of, or known to be positive for, HIV, hepatitis B or C * Subjects with uncontrolled hypertension as defined by systolic blood pressure (SBP) \> 150 mm/Hg, diastolic blood pressure (DBP) \> 100 mm/Hg * Subjects with a wound or skin irritation or any skin condition, e.g., psoriasis in the treatment area * Subjects who are taking prescription medications with the exception of oral or systemic contraceptives * Subjects who have systemic diseases * Subjects who have a history of anaphylactic reactions to any systemic or topical compounds
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recording of adverse events | Part A - during the 7 days following the application of the study drug and Part B during the 14 day following each application of the study drug | Adverse events will be described with respect to seriousness, intensity, relationship to treatment, action taken and outcome of the event. Local skin irritation will be assessed at each visit based on individual signs and symptoms of skin tolerability for erythema, pruritus, scaling/dryness, edema and stinging/burning. |
Secondary
| Measure | Time frame |
|---|---|
| Area under the Concentration curve (AUC) | Part A - Pre-dose, 15 minutes, 30 minutes, 1, 2, 4 and 6 hours post dose and Days 2, 3 and 7. Part B - Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, and 6 hours post dose, Days 2, 3 (15 minutes, 30 minutes, 1, 2, 4 and 6 hours post dose) Days 4, 7 and 14 |
Countries
United States
Outcome results
None listed